Hims & Hers Health (NYSE:HIMS) Insider Sells $97,965.14 in Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,458 shares of the firm’s stock in a transaction dated Wednesday, September 2nd. The shares were sold at an average price of $28.33, for a total value of $97,965.14. Following the completion of the transaction, the insider owned 310,506 shares of the company’s stock, valued at $8,796,634.98. The trade was a 1.10% decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Stock Performance

Shares of NYSE HIMS opened at $27.66 on Friday. The company has a debt-to-equity ratio of 4.21, a quick ratio of 0.87 and a current ratio of 0.93. The stock has a 50 day moving average price of $31.67 and a 200 day moving average price of $26.75. The stock has a market capitalization of $6.45 billion, a PE ratio of -43.90 and a beta of 2.42. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $65.30.

Hims & Hers Health (NYSE:HIMS) last posted its quarterly earnings results on Monday, August 10th. The company reported ($0.37) earnings per share for the quarter, missing the consensus estimate of ($0.05) by ($0.32). Hims & Hers Health had a negative return on equity of 6.51% and a negative net margin of 5.51%.The company had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period last year, the firm earned $0.17 EPS. The firm’s revenue for the quarter was up 38.2% compared to the same quarter last year.

Institutional Inflows and Outflows

Large investors have recently added to or reduced their stakes in the business. Binnacle Investments Inc bought a new stake in shares of Hims & Hers Health in the third quarter worth $28,000. Versant Capital Management Inc raised its position in shares of Hims & Hers Health by 801.2% during the second quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock worth $26,000 after acquiring an additional 665 shares during the last quarter. MassMutual Private Wealth & Trust FSB lifted its stake in shares of Hims & Hers Health by 70.0% in the second quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock worth $27,000 after acquiring an additional 319 shares during the period. Silicon Valley Capital Partners acquired a new position in shares of Hims & Hers Health in the third quarter worth approximately $48,000. Finally, EverSource Wealth Advisors LLC boosted its holdings in Hims & Hers Health by 273.7% in the second quarter. EverSource Wealth Advisors LLC now owns 938 shares of the company’s stock valued at $47,000 after acquiring an additional 687 shares during the last quarter. Institutional investors own 63.52% of the company’s stock.

Analyst Upgrades and Downgrades

A number of brokerages have recently commented on HIMS. Weiss Ratings reissued a “sell (d)” rating on shares of Hims & Hers Health in a research report on Friday, August 7th. Canaccord Genuity Group raised their target price on shares of Hims & Hers Health from $32.00 to $40.00 and gave the company a “buy” rating in a research note on Wednesday, July 1st. UBS Group set a $23.00 price target on Hims & Hers Health in a report on Friday, May 22nd. TD Cowen boosted their price target on Hims & Hers Health from $25.00 to $30.00 and gave the stock a “hold” rating in a research report on Tuesday, August 11th. Finally, Morgan Stanley raised their price objective on Hims & Hers Health from $21.00 to $28.00 and gave the company an “equal weight” rating in a research report on Tuesday, August 11th. Four research analysts have rated the stock with a Buy rating, eleven have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Hold” and an average price target of $32.50.

Key Stories Impacting Hims & Hers Health

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: Hims & Hers continues to show strong top-line momentum: second-quarter revenue rose 38.2% year over year to $753.2 million and exceeded analyst expectations. The company also raised its 2026 revenue outlook, supported by weight-loss treatments, international expansion and artificial-intelligence initiatives. HIMS Raises 2026 Revenue Outlook as Q2 Sales Rise 38.2% Despite Loss
• Neutral Sentiment: Analyst sentiment remains cautious. The consensus rating is “Hold,” with analysts recognizing the company’s growth opportunities while citing profitability pressure and uncertainty related to regulatory oversight.
• Negative Sentiment: Several investor-rights firms announced or promoted a securities-fraud class action against Hims & Hers and certain executives. The case covers investors who acquired securities between August 4, 2025, and July 29, 2026; investors must move for lead-plaintiff status by November 2, 2026. The repeated announcements increase concerns about potential legal expenses, penalties, management distraction and reputational damage. Rosen Law Firm HIMS Class Action Announcement
• Negative Sentiment: The litigation is tied to allegations stemming from an FTC complaint, including potentially deceptive privacy and billing practices. Claims that consumer health information may have been shared with advertising platforms and that customers may have been charged soon after submitting prescription-intake forms create risks of enforcement actions and additional compliance costs. These claims remain allegations. Kessler Topaz HIMS Investor Alert
• Negative Sentiment: Insider Soleil Boughton sold 3,458 shares for approximately $98,000 under a pre-arranged Rule 10b5-1 trading plan. The transaction reduced the insider’s holdings by about 1.1%, making it a relatively small and scheduled sale, but it adds a modest negative signal amid the broader legal uncertainty. Hims & Hers Insider Sale

Hims & Hers Health Company Profile

Hims & Hers Health, Inc is a telehealth platform providing direct-to-consumer personal care products and virtual medical services in the United States. Operating under the Hims & Hers brand, the company offers an integrated digital experience that connects users with licensed healthcare providers, enabling online consultations and prescriptions for a range of conditions. Its telemedicine infrastructure supports both prescription medications and over-the-counter products, with home delivery to patients’ doorsteps.

The company’s product portfolio addresses key areas of men’s and women’s health, including hair loss treatments, sexual wellness therapies, skincare regimens and mental health support.